Stock Detail
CURIS INC
Biotechnology
CRIS @ Yahoo Finance | CRIS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.66 | $3.78 | $0.00 | 0.00% | 0.00 | $3.79 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $3.75 | $3.65 | 362,268 | 280.28M | 379,097.5 | 0.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.83 | 3.75 | 3.70 | 3.62 | 3.57 |
Stock Profile
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter & Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.